Annual drug greatly reduces risk of bone breaks in menopause

Postmenopausal women can take the drug Aclasta intravenously just once a year to reduce their risk of breaking bones, a new study concludes. The drug, which Novartis Pharmaceuticals Corp. plans to market in the U.S. as Reclast, was shown in studies to reduce the risk of spine fractures by 70% and hip fractures by 41%.

View Full Article in:

BBC · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC